Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data
Therapeutic Advances in Musculoskeletal Disease · 2026-05 · 18
DOI: 10.1177/1759720x261439725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 04.05.2026. Verfasst von Wolfgang A Schmidt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Waldfriede Hospital, Rheumatology, Argentinische Allee 40, Berlin 14163, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis GmbH.
Abstract (Originalsprache)
Background
For giant cell arteritis (GCA), a north-south gradient in incidence and prevalence has been described, peaking in Scandinavia.
Objective
This analysis aimed to obtain up-to-date, representative data on the prevalence and incidence of GCA in Germany, updating the old, regional information on low incidence and prevalence rates.
Design
Cross-sectional analysis using a large German health insurance database.
Methods
This study is based on a cross-sectional analysis of claims data from the InGef (Institute for Health Research Berlin GmbH) research database, which includes a representative sample of 4.8 million insured individuals. Individuals aged ⩾50 years with continuous insurance coverage for a 3-year baseline period and the subsequent 2 years for longitudinal analysis were included. Estimates were standardised and projected to the German population.
Results
Each year from 2018 to 2021, 1.7 million insured individuals met the inclusion and exclusion criteria. Extrapolated to the German population ⩾50 years in 2021, the incidence was 24/100,000, and the prevalence was 146/100,000. Diagnosis was made predominantly in outpatient settings by general practitioners (GP, 31.9%) and internists (19.5%), followed by rheumatologists (13.1%) and ophthalmologists (5.7%). Within 2 years, 16.3% of incident patients were referred to rheumatologists for treatment after diagnosis. Treatment was most commonly initiated by GPs (45.8%), followed by rheumatologists (36.1%), and included glucocorticoids (88.2%), methotrexate (26.7%), and tocilizumab (14.1%). Most common comorbidities of prevalent patients comprised arterial hypertension (77.2%), dyslipidaemia (55.0%), diabetes mellitus (28.8%), osteoporosis (34.6%), and cataract (31.2%).
Conclusion
Contrary to previous reports, Germany has higher incidence and prevalence rates of GCA than previously assumed. Only approximately one-third of the incident patients were initially treated by rheumatologists. Comorbidities such as diabetes or cardiovascular diseases were common.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Waldfriede Hospital, Rheumatology, Argentinische Allee 40, Berlin 14163, Germany.
- InGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
- Novartis Pharma GmbH, Nürnberg, Germany.
- Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany.
ORCID-Profile: Wolfgang A Schmidt, Marco Alibone, Nils Venhoff
Förderung
- Novartis GmbH
Zitieren
APA
Schmidt, W. A., Alibone, M., Ludwig, P., Obermüller, D., Karl, F., Terner, S., & Venhoff, N. (2026). Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261439725
Vancouver
Schmidt WA, Alibone M, Ludwig P, Obermüller D, Karl F, Terner S, et al. Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261439725
BibTeX
@article{Schmidt2026,
author = {Schmidt, Wolfgang A and Alibone, Marco and Ludwig, Paul and Obermüller, Dominik and Karl, Franziska and Terner, Stephanie and Venhoff, Nils},
title = {Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2026},
volume = {18},
doi = {10.1177/1759720x261439725}
}
EUVIMED